Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of house dust mite allergoid immunotherapy in allergic asthma
2004-003892-35Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Nov 2004
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic asthma, allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and 1 more comparing House dust mite allergoid with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Nov 2004; status: completed.
02
Drugs
Acaroid
03
Conditions
allergic asthmaallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2004-003892-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003892-35.